Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19.

Autors de IIS La Fe
Autors aliens a IIS La Fe
- Rodilla E
- Saura A
- Jiménez I
- Mendizábal A
- Pineda-Cantero A
- Lorenzo-Hernández E
- Fidalgo-Montero MDP
- López-Cuervo JF
- Rabadán-Pejenaute E
- Abella-Vázquez L
- Giner-Galvañ V
- Solís-Marquínez MN
- Boixeda R
- Peña-Fernández A
- Carrasco-Sánchez FJ
- González-Moraleja J
- Torres-Peña JD
- Guisado-Espartero ME
- Escobar-Sevilla J
- Guzmán-García M
- Martín-Escalante MD
- Martínez-González ÁL
- Casas-Rojo JM
- Gómez-Huelgas R
Grups d'Investigació
Abstract
It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.
Dades de la publicació
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipus:
- Article
- Pàgines:
- -
- DOI:
- 10.3390/jcm9103136
- PubMed:
- 32998337
Journal of clinical medicine MDPI AG
Cites Rebudes en Web of Science: 56
Documents
- No hi ha documents
Filiacions
Keywords
- COVID-19, all-cause mortality, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), hypertension
Projectes associats
SUBREGISTRO PROSPECTIVO, MULTICÉNTRICO Y OBSERVACIONAL DE SEGURIDAD POSTAUTORIZACIÓN PARA CARACTERIZAR EL PERFIL DE SEGURIDAD A LARGO PLAZO DEL USO COMERCIAL DE ELIGLUSTAT (CERDELGA®) EN PACIENTES ADULTOS CON ENFERMEDAD DE GAUCHER.
Investigador Principal: PATRICIA CORRECHER MEDINA
OBS14099 . 2018
MEMORIA PARA EL ESTUDIO DE ESPLENOMEGALIA Y PACIENTES ESPLENECTOMIZADOS NO FILIADOS EN POBLACIÓN INFANTIL Y ADULTA.
Investigador Principal: ISIDRO VITORIA MIÑANA
PREDIGA . 2020